申请人:Optikira, LLC
公开号:US20220194945A1
公开(公告)日:2022-06-23
The present invention provides novel imidazolopyrazine compounds, compositions and methods for treating or preventing an IRE1α-related disease or disorder. In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease, a demyelinating disease, cancer, an eye disease, a fibrotic disease, and diabetes.